Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab emtansine (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms TEAL
- 12 Apr 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 23 Jul 2018 Status changed from completed to active, no longer recruiting.